Aptorum Group (NASDAQ:APM) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Aptorum Group (NASDAQ:APM) from a sell rating to a hold rating in a research note released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aptorum Group in a research note on Wednesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Aptorum Group Price Performance

APM opened at $1.66 on Friday. Aptorum Group has a one year low of $0.46 and a one year high of $7.49. The company’s 50 day simple moving average is $1.87 and its 200-day simple moving average is $1.33.

Aptorum Group Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.